Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety ProfileKeyu Li, Bruce A. Keyt, Rui Yun et al.|Blood|2022Cited by 10
GPR30 decreases with vascular aging and promotes vascular smooth muscle cells maintaining differentiated phenotype and suppressing migration via activation of ERK1/2Xiangping Li, Min Wang, Fang Huang et al.|OncoTargets and Therapy|2016Cited by 8
Abstract 5664: A bispecific IgM antibody format for enhanced T cell dependent killing with minimal cytokine releaseRamesh Baliga, Bruce A. Keyt, Keyu Li et al.|Cancer Research|2020Cited by 3
Abstract 2959: Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent mechanismsKeyu Li, Bruce A. Keyt, Rui Yun et al.|Cancer Research|2023Cited by 2
Abstract 4179: High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killingKevin C. Hart, Maya F. Kotturi, Kathryn Logronio et al.|Cancer Research|2022Cited by 1